More preferred therapeutics are being developed in such a way that they selectively target cancer cells and treatment with tumor necrosis factor–related apoptosis inducing ligand (TRAIL) is considered to be promising because of its naturally proapoptotic properties specifically directed to cancer cells (Wong et al., 2019). The gene discussed is TNFSF10; the disease is cancer.